683 Capital Management’s HilleVax HLVX Stock Holding History

683 Capital Management’s Portfolio HLVX Stock Details HLVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-140,000	Closed	-$2.02M	–	148
2024 Q2	$2.02M	Buy	140,000 +27,000	+24%	+$371K	0.15%	90
2024 Q1	$1.88M	Sell	113,000 -8,200	-7%	-$131K	0.14%	80
2023 Q4	$1.95M	Hold	121,200	–	–	0.16%	79
2023 Q3	$1.63M	Buy	+121,200	New	+$1.71M	0.13%	89

Other funds holding HLVX

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

683 Capital Management's HLVX Position: Q3 2024 in Review

683 Capital Management sold out of HilleVax (HLVX) in Q3 2024, closing a stake of 140,000 shares — an estimated $2.02M sold.

683 Capital Management first reported a position in HLVX in Q3 2023 and held it in 4 quarters. The position peaked at $2.02M in Q2 2024. 79 funds tracked by Wall St. Rank hold HLVX as of Q3 2024.

683 Capital Management reported no remaining HilleVax position as of Q3 2024 after selling out during the quarter.
683 Capital Management sold 140,000 HilleVax shares in Q3 2024, an estimated $2.02M.
683 Capital Management first reported a position in HilleVax in Q3 2023 and held it in 4 quarters.
683 Capital Management's HilleVax position peaked at $2.02M in Q2 2024.
79 funds tracked by Wall St. Rank held HilleVax as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.